Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterised by insulin resistance, impaired pancreatic beta cell function, dysregulated glucagon secretion, altered incretin activity, increased hepatic glucose production and abnormal renal glucose handling. The growing burden of T2DM and its related cardiovascular, renal and metabolic complications has led to a change in focus from conventional glucose-lowering therapy to pharmacological strategies that address broader metabolic and clinical outcomes. This review provides a comprehensive overview of established and emerging pharmacological approaches for managing T2DM, emphasising their therapeutic targets, mechanisms of action, clinical applications, benefits and limitations. The review discusses established therapies, including metformin, sulfonylureas, meglitinides, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and insulin, in relation to their roles in contemporary diabetes management. The review also examines combination and fixed-dose therapies, as well as the importance of tailoring treatment to an individual's glycaemic status, body weight, cardiovascular risk, renal function, comorbidities, tolerability and treatment response. Recent therapeutic developments are also explored, including dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, oral and non-peptide GLP-1 receptor agonists, glucagon receptor-targeted approaches, and strategies aimed at β-cell protection and regeneration. The potential of emerging approaches involving stem cell- and gene-based interventions to address the underlying pathophysiology of T2DM is also considered. Overall, the pharmacological management of type 2 diabetes mellitus (T2DM) is evolving towards strategies that are both mechanism-based and patient-centred, integrating glycaemic control with cardiovascular, renal, metabolic and weight-related outcomes. Further investigation of emerging therapies may expand the range of options available for long-term disease management.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: